Summer Sale

Up to 30% off — ends 7 Aug

ONLY00h00m00s

Get 30% Off

Up to 30% off — ends 7 Aug

ONLY00h00m00s

Brendon Neuen

The George Institute for Global Health

Australia

This profile is automatically generated from trusted academic sources.

Google Scholar

ORCID

How do I reach out?

Meet Kite AI

Contact this professor

LinkedIn ORCID

Google Scholar

Academic Page

Research Interests

Clinical Nutrition

80%

Cardiology

20%

Kidney Disease

40%

Diabetology

40%

Cardiometabolic Health

40%

Insulin Resistance

30%

Type 2 Diabetes

30%

Ask ApplyKite AI

Start chatting

How can you help me contact this professor?

What are this professor's research interests?

How should I write an email to this professor?

Articles10

The sodium‐glucose cotransporter‐2 inhibitor canagliflozin does not increase risk of non‐genital skin and soft tissue infections in people with type 2 diabetes mellitus: A pooled post hoc analysis from the CANVAS Program and CREDENCE randomized double‐blind trials

Article Link

Year:

2023

The effects of canagliflozin in type 2 diabetes in subgroups defined by population‐specific body mass index: Insights from the CANVAS Program and CREDENCE trial

Article Link

Year:

2023

Estimated lifetime benefit of novel pharmacological therapies in patients with type 2 diabetes and chronic kidney disease: A joint analysis of randomized controlled clinical trials

Article Link

Year:

2023

Kidney protection with canagliflozin: A combined analysis of the randomized CANVAS program and CREDENCE trials

Article Link

Year:

2023

Cardiovascular and kidney outcomes with canagliflozin according to type 2 diabetes treatment targets at baseline: Data from the CANVAS programme and CREDENCE

Article Link

Year:

2023

Effects of canagliflozin on cardiovascular and kidney events in patients with chronic kidney disease with and without peripheral arterial disease: Integrated analysis from the CANVAS Program and CREDENCE trial

Article Link

Year:

2023

A meta-analysis of GFR slope as a surrogate endpoint for kidney failure.

Article Link

Year:

2023

Canagliflozin, Blood Pressure Variability, and Risk of Cardiovascular, Kidney, and Mortality Outcomes: Pooled Individual Participant Data From the CANVAS and CREDENCE Trials.

Article Link

Year:

2023

Empagliflozin in Patients with Chronic Kidney Disease.

Article Link

Year:

2023

Glycemic Control and Effects of Canagliflozin in Reducing Albuminuria and eGFR

Article Link

Year:

2023

Collaborators13

Hiddo Lambers Heerspink

University of Groningen

NETHERLANDS

Michael Tsoukas

Assistant Professor of Medicine

McGill University Health Centre

CANADA

Clare Arnott

AUSTRALIA

Rajiv Agarwal

Professor of Medicine

Indiana State University

UNITED STATES

Jasper Stevens

NETHERLANDS

Pardeep Jhund

University of Glasgow

UNITED KINGDOM

Jochen Seufert

GERMANY

Gian Luca Di Tanna

Visiting Professor

University of New South Wales

AUSTRALIA

george bakris

Professor of medicine, Director AHA Comprehensive Hypertension Center

University of Chicago

UNITED STATES

Kieran Docherty

University of Glasgow

UNITED KINGDOM

Megumi Oshima

Kanazawa University

JAPAN

Adeera Levin

CANADA

Lauren Houston

Conjoint Lecturer

University of New South Wales - Randwick Campus

AUSTRALIA

How do I reach out?

Meet Kite AI